01—Abstract
Summary
Summary of the 8-K filed July 22, 2025. Cited figures are marked; the original filing is the authoritative source.
Danaher reported second-quarter 2025 results for the quarter ended June 27, 2025, with revenue up 3.5% year-over-year to $5.9 billiona, but GAAP profitability fell sharply.
Net earnings were $555 millionb, or $0.77 per diluted share, versus $907 million, or $1.22, a year earlier. The decline is driven by a $432 million pretax impairment of a Life Sciences trade name, along with higher SG&A expenses ($2.36 billion vs. $1.87 billion) and much lower interest income ($8 million vs. $39 million). Excluding these and other items, adjusted diluted EPS rose to $1.80 from $1.72, about 5%, and management said results exceeded its expectations.
Underlying growth was more modest than headline sales growth suggests. Non-GAAP core revenue grew 1.5%c, with currency adding roughly 2 points. Biotechnology was the standout, with core sales up 6.0%, while Life Sciences declined 2.5% on a core basis and Diagnostics grew 2.0%.
Operating cash flow was $1.3 billiond and free cash flow was $1.1 billion, both broadly flat with the prior year. Six-month GAAP net earnings were $1.51 billion versus $2.00 billion, reflecting the same charges. Looking ahead, management expects third-quarter core revenue growth in the low-single digits and maintained full-year core growth of about 3%.
It raised full-year adjusted diluted EPS guidance to $7.70–$7.80 from $7.60–$7.75. Management says the macro environment remains fluid, and the filing lists tariffs, currency, and Life Sciences trade name impairment risk among the factors to watch.
02—Key points
Key Highlights
- GAAP diluted EPS fell to $0.77 from $1.22 (about -37%), mainly due to a $432 million pretax impairment of a Life Sciences trade name, which contributed $0.60 per share.
- Adjusted diluted EPS rose to $1.80 from $1.72 (about +5%), beating the company's expectations and reflecting cost discipline.
- Revenue grew 3.5% to $5.9 billion, but core (organic, ex-FX and M&A) revenue grew only 1.5%; currency contributed about 2 points.
- Biotechnology was the growth engine with 6.0% core growth, while Life Sciences declined 2.5% on a core basis and Diagnostics grew 2.0%.
- Full-year 2025 adjusted diluted EPS guidance was raised to $7.70–$7.80 from $7.60–$7.75, while full-year core growth guidance of about 3% was unchanged.
- Third-quarter core revenue growth is guided to low-single digits, a slower pace than the full-year 3% target implies for the second half if the first half is taken into account.
- Operating cash flow was $1.34 billion and free cash flow was $1.09 billion, slightly below the prior year's $1.13 billion, with the cash generation metric holding up despite the GAAP earnings decline.
03—Questions
Frequently Asked Questions
Why did GAAP earnings fall so much when revenue grew?
The main driver is a $432 million pretax impairment of a trade name in the Life Sciences segment, which reduced GAAP diluted EPS by about $0.60 per share. SG&A also rose to $2.36 billion from $1.87 billion, and interest income fell to $8 million from $39 million. The filing does not itemize the SG&A increase, so the impairment is a likely contributor but not the only one. Adjusted EPS, which excludes amortization, impairments, and investment gains and losses, still rose about 5%.
How strong is the underlying business growth?
Core revenue growth of 1.5% is modest. Strength came from Biotechnology (+6.0% core), while Life Sciences (-2.5%) was a drag and Diagnostics (+2.0%) grew moderately. Reported growth of 3.5% was flattered by roughly 2 points of favorable currency movement. Six-month core growth was 1.0%.
What is the outlook for the rest of 2025?
Management maintained full-year 2025 core revenue growth of about 3% and expects low-single-digit core growth in the third quarter. It raised adjusted diluted EPS guidance to $7.70–$7.80 from $7.60–$7.75. The company cites tariffs, currency fluctuations, and an uncertain macro environment as risks. Full-year currency is expected to add about 1.0% to revenue growth.
Is Danaher still generating strong cash flow?
Yes. Operating cash flow was $1.34 billion in the quarter, slightly below the prior year's $1.42 billion. After capital expenditures of $248 million, free cash flow was $1.09 billion, compared with $1.13 billion a year earlier. Cash used in financing fell sharply to $247 million from $5.7 billion, reflecting the absence of a large prior-year debt-related outflow.
04—Continue